These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 28628468)

  • 1. DAPSA, DAS28 and MDA predict long-term treatment regime in psoriatic arthritis. The Swedish Early Psoriatic Arthritis Cohort.
    Lindqvist U; Wernroth ML; Husmark T; Larsson P; Geijer M; Teleman A; Theander E; Alenius GM
    Clin Exp Rheumatol; 2017; 35(6):936-942. PubMed ID: 28628468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA).
    Theander E; Husmark T; Alenius GM; Larsson PT; Teleman A; Geijer M; Lindqvist UR
    Ann Rheum Dis; 2014 Feb; 73(2):407-13. PubMed ID: 23355078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study.
    Michelsen B; Kristianslund EK; Hammer HB; Fagerli KM; Lie E; Wierød A; Kalstad S; Rødevand E; Krøll F; Haugeberg G; Kvien TK
    Ann Rheum Dis; 2017 Apr; 76(4):708-711. PubMed ID: 27707730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
    Perrotta FM; Marchesoni A; Lubrano E
    J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population.
    Michelsen B; Diamantopoulos AP; Høiberg HK; Soldal DM; Kavanaugh A; Haugeberg G
    J Rheumatol; 2017 Apr; 44(4):431-436. PubMed ID: 28148701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
    Lubrano E; De Socio A; Perrotta FM
    J Rheumatol; 2017 Aug; 44(8):1159-1164. PubMed ID: 28572467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of interleukin-17A inhibitor in Japanese patients with psoriatic arthritis compared with tumor necrosis factor-alpha inhibitor.
    Izumiyama T; Mori Y; Oizumi I; Hamada S; Kurishima H; Terui H; Omori-Shimada R; Yamasaki K; Itoi E
    J Orthop Surg (Hong Kong); 2021; 29(2):23094990211012286. PubMed ID: 33938296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors.
    Chimenti MS; Triggianese P; Conigliaro P; Tonelli M; Gigliucci G; Novelli L; Teoli M; Perricone R
    Clin Rheumatol; 2017 Oct; 36(10):2253-2260. PubMed ID: 28762060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study.
    Chimenti MS; Ortolan A; Lorenzin M; Triggianese P; Talamonti M; Costa L; Caso F; Favero M; Teoli M; Galluzzo M; Scarpa R; Punzi L; Perricone R; Ramonda R
    Clin Rheumatol; 2018 Feb; 37(2):397-405. PubMed ID: 29302829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors.
    Lubrano E; Parsons WJ; Perrotta FM
    J Rheumatol; 2016 May; 43(5):918-23. PubMed ID: 26980581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?
    Kilic G; Kilic E; Nas K; Kamanlı A; Tekeoglu İ
    Rheumatol Int; 2019 Jan; 39(1):73-81. PubMed ID: 30426235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.
    Glintborg B; Ostergaard M; Krogh NS; Andersen MD; Tarp U; Loft AG; Lindegaard HM; Holland-Fischer M; Nordin H; Jensen DV; Olsen CH; Hetland ML
    Arthritis Rheum; 2013 May; 65(5):1213-23. PubMed ID: 23460467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of methotrexate and tumor necrosis factor inhibitors in Japanese patients with active psoriatic arthritis.
    Mori Y; Kuwahara Y; Chiba S; Itoi E
    Mod Rheumatol; 2015 May; 25(3):431-4. PubMed ID: 25295919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis.
    Wervers K; Vis M; Tchetveriko I; Gerards AH; Kok MR; Appels CWY; van der Graaff WL; van Groenendael JHLM; Korswagen LA; Veris-van Dieren JJ; Hazes JMW; Luime JJ
    Arthritis Care Res (Hoboken); 2018 Dec; 70(12):1764-1770. PubMed ID: 29609220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Swedish early psoriatic arthritis register-- 2-year followup: a comparison with early rheumatoid arthritis.
    Lindqvist UR; Alenius GM; Husmark T; Theander E; Holmström G; Larsson PT;
    J Rheumatol; 2008 Apr; 35(4):668-73. PubMed ID: 18278834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible.
    Palsson O; Love TJ; Gunnarsdottir AI; Gunnarsson PS; Runarsdottir EE; Krogh NS; Gudbjornsson B
    RMD Open; 2019; 5(2):e000984. PubMed ID: 31413869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers.
    Iervolino S; Di Minno MN; Peluso R; Lofrano M; Russolillo A; Di Minno G; Scarpa R
    J Rheumatol; 2012 Mar; 39(3):568-73. PubMed ID: 22247361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrasonographic evaluation in psoriatic arthritis is of major importance in evaluating disease activity.
    Michelsen B; Diamantopoulos AP; Hammer HB; Soldal DM; Kavanaugh A; Haugeberg G
    Ann Rheum Dis; 2016 Dec; 75(12):2108-2113. PubMed ID: 27091837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient's Global Assessment as an Outcome Measure for Psoriatic Arthritis in Clinical Practice: A Surrogate for Measuring Low Disease Activity?
    Lubrano E; Perrotta FM; Parsons WJ; Marchesoni A
    J Rheumatol; 2015 Dec; 42(12):2332-8. PubMed ID: 26523033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.
    Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Lexberg AS; Rødevand E; Kalstad S; Mikkelsen K; Kvien TK
    Ann Rheum Dis; 2014 Jan; 73(1):132-7. PubMed ID: 23291385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.